Artax Biopharma: Artax Biopharma concludes subject recruitment in autoimmune disease trial
Artax Biopharma has announced the conclusion of recruitment in its Phase IIa clinical trial of AX-158, aimed at treating autoimmune diseases. The post Artax Biopharma concludes subject recruitment in autoimmune disease trial appeared first on Clinical Trials Arena.
Read full article »
Artax is a Massachusetts-based clinical-stage biotechnology company that researches and develops T-cell therapeutics for the treatment of autoimmune diseases.
Read more